Gamida Cell Shares Up 34% on FDA Approval of Omisirge Cell Therapy for Blood Cancer
April 17 2023 - 2:30PM
Dow Jones News
By Josh Beckerman
Gamida Cell Ltd. shares rose 34% to $1.08 Monday after the U.S.
Food and Drug Administration approved the Boston-based
biotechnology company's Omisirge cell therapy for certain blood
cancer patients.
Omisirge is a substantially modified allogeneic cord blood-based
cell therapy aimed at quickening the recovery of neutrophils and
reducing the risk of infection.
The cell therapy was approved by the FDA for patients 12 years
and older with blood cancers who undergo umbilical cord blood
transplantation following a myeloablative conditioning regimen.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 17, 2023 14:15 ET (18:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Jul 2023 to Jul 2024
